Literature DB >> 9496384

Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials.

B R Voldborg1, L Damstrup, M Spang-Thomsen, H S Poulsen.   

Abstract

The epidermal growth factor receptor (EGFR) is a growth factor receptor that induces cell differentiation and proliferation upon activation through the binding of one of its ligands. The receptor is located at the cell surface, where the binding of a ligand activates a tyrosine kinase in the intracellular region of the receptor. This tyrosine kinase phosphorylates a number of intracellular substrates that activates pathways leading to cell growth, DNA synthesis and the expression of oncogenes such as fos and jun. EGFR is thought to be involved the development of cancer, as the EGFR gene is often amplified, and/or mutated in cancer cells. In this review we will focus on: (I) the structure and function of EGFR, (II) implications of receptor/ligand coexpression and EGFR mutations or overexpression, (III) its effect on cancer cells, (IV) the development of the malignant phenotype and (V) the clinical aspects of therapeutic targeting of EGFR.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9496384     DOI: 10.1023/a:1008209720526

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  103 in total

1.  Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase.

Authors:  Z Lu; G Jiang; P Blume-Jensen; T Hunter
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

2.  Src defines a new pool of EGFR substrates.

Authors:  Nicole Michael; Natalia Jura
Journal:  Nat Struct Mol Biol       Date:  2015-12       Impact factor: 15.369

3.  α-Catenin inhibits glioma cell migration, invasion, and proliferation by suppression of β-catenin transactivation.

Authors:  Haitao Ji; Ji Wang; Bingliang Fang; Xuexun Fang; Zhimin Lu
Journal:  J Neurooncol       Date:  2010-09-26       Impact factor: 4.130

Review 4.  Intraoperative imaging in ovarian cancer: fact or fiction?

Authors:  Lucia M A Crane; Marleen van Oosten; Rick G Pleijhuis; Arash Motekallemi; Sean C Dowdy; William A Cliby; Ate G J van der Zee; Gooitzen M van Dam
Journal:  Mol Imaging       Date:  2011-04-26       Impact factor: 4.488

5.  The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis.

Authors:  M Zhou; M T Mok; H Sun; A W Chan; Y Huang; A S Cheng; G Xu
Journal:  Oncogene       Date:  2017-03-20       Impact factor: 9.867

6.  EGF enhances low-invasive cancer cell invasion by promoting IMP-3 expression.

Authors:  Xianglan Zhang; Im-Hee Jung; Young Sun Hwang
Journal:  Tumour Biol       Date:  2015-09-19

7.  A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  G Goss; H Hirte; W H Miller; I A J Lorimer; D Stewart; G Batist; D A E Parolin; P Hanna; S Stafford; J Friedmann; W Walsh; S Mathews; L Douglas; L K Seymour
Journal:  Invest New Drugs       Date:  2005-03       Impact factor: 3.850

Review 8.  Pharmacotherapeutic management of pediatric gliomas : current and upcoming strategies.

Authors:  Trent R Hummel; Lionel M Chow; Maryam Fouladi; David Franz
Journal:  Paediatr Drugs       Date:  2013-02       Impact factor: 3.022

9.  Version control of pathway models using XML patches.

Authors:  Peter Saffrey; Richard Orton
Journal:  BMC Syst Biol       Date:  2009-03-17

10.  Computational modelling of cancerous mutations in the EGFR/ERK signalling pathway.

Authors:  Richard J Orton; Michiel E Adriaens; Amelie Gormand; Oliver E Sturm; Walter Kolch; David R Gilbert
Journal:  BMC Syst Biol       Date:  2009-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.